A Modern Approach to
Cancer Testing

IONIQ Sciences is at the forefront of early cancer detection

Cancer is a scourge on society. One in two Americans will be diagnosed with cancer during their lifetime and one in five will die. The five-year cancer survival rates approach 90% when diagnosed in the earliest stages of the disease versus just 10% in the latest stages. 

We believe it doesn’t have to be this way. 

Expanding from a Single Cancer
Test to a
Multi-Cancer Screen

Early detection saves lives and money by detecting cancer at its earliest, most-treatable stages. We are well-positioned to develop a Multi-Cancer Screen by leveraging our lung test, breast test, proprietary technology, substantial EIA database, and our deep clinical experience.

IONIQ Development Pipeline

ProLung Test (Lung Cancer)
Breast Cancer Test
Multi-Cancer Screen

Clinical Data

Assembled a deep clinical evidence library with data collected from more than 1,200 subjects

Premier Clinical Sites

More than 20 premier cancer institutions around the world participated in our clinical trials

Awarded Breakthrough Device Designation

IONIQ's ProLung Test was awarded “Breakthrough Device Designation” by US FDA for its life-enhancing potential

Intellectual Property

Robust, growing intellectual portfolio of patents and know-how

15 yrs
in the Making

IONIQ Recent News

IONIQ Sciences Awarded Another Patent

IONIQ Sciences awarded another patent for “an apparatus for providing information that is useful in the diagnosis of a malignant lung lesion” IONIQ’s newest Notice of Allowance by the State Intellectual Property Office of the People’s Republic of China (SIPO) covers critical advancements and refinements

BIO Announces IONIQ Sciences as Finalist for Buzz of BIO 2021 Award

BIO has just now announced that IONIQ Sciences is a finalist for their prestigious ‘Buzz of BIO 2021’ award.  Please click HERE to vote for IONIQ Sciences in the ‘Diagnostics and Beyond’ category! Just click “Vote for this Company” and take 30 seconds to set up a voting profile. Voting closes

IONIQ awarded 2020 Business Excellence Award by Silicon Review

IONIQ has been awarded the 2020 Business Excellence Award by Silicon Review. We’re proud of the progress we made last year in our pursuit of a point-of-care (POC) screening device to help counter this nation’s second leading cause of death. Cancer killed more than 600,000 Americans

Standards & Certifications

Meet the Team

Proud to be part of BioHive, the Nations Fastest Growing Life Science Hub.

By embracing diversity and collaboration, BioHive has become the fastest-growing life science community in America. And our innovations are improving the lives of millions of patients.